Rev Esp Quimioter 2022; 35(3): 260-264

Retrospective observational study of the persistence of SARS-CoV-2 infection in patients previously treated with rituximab

MARÍA TERESA GÓMEZ LLUCH, BEATRIZ PROY VEGA, MARTÍN CABERO BECERRA, ÁLVARO RODRÍGUEZ, ALBERTO ESCALERA ZALVIDE, SIMÓN ÁNGEL SÁNCHEZ

Published: 10 March 2022

http://www.doi.org/10.37201/req/122.2022

Introduction. Rituximab-induced immunosuppression could be a risk factor for mortality from COVID-19. The aim of the study was to describe the prevalence of SARS-CoV-2 infection in patients who have received rituximab and its association with a persistent viral infection
Material and methods. Retrospective observational study of patients who received rituximab in the 6 months before to the onset of the pandemic. We analyzed the presence of infection and associated them with demographic variables, pathological history related to an increased risk of developing severe COVID-19, the doses of rituximab received, the type of ventilatory support, thromboembolic events, and the treatment received. A descriptive analysis of all the variables was carried out and infected and uninfected patients were compared.
Results. We screened a total of 68 patients who had received rituximab (median cumulative dose: 4,161mg (2,611–8,187.5)). 54.4% men, mean age 60.8 years (15.7; 25-87)). C + was confirmed for 22 patients. Of these, 45.5% had high blood pressure, 36.4% Diabetes Mellitus, 31.8% smokers/ex-smoker, 22.7% lung disease, 13.6% heart disease and 4.5% obesity. There were no statistically significant differences between C+ and C-. Only 2 patients developed immunity. For 10 patients (45.5%) did not have a negative CRP until the end of the follow-up. There was no association with cumulative dose of rituximab. The mortality rate was 22.7% in the C+.
Conclusions. We observe that the persistence of the infection leads to a worse evolution of COVID-19. The use of alternatives should be considered during the pandemic, because of patients with decreased B-cell function may have high risk of fatal progression from COVID-19.

Rev Esp Quimioter 2022; 35(3): 260-264 [Texto completo PDF]